Raymond James Thinks Haemonetics Growth Is ‘Underappreciated’
Earlier this week, Raymond James attended Haemonetics Corp’s (NYSE:HAE) Investor Day, where the management team presented a new Long-Range Plan (LRP), including…
Takeda’s Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Endo Posts Disappointing Data From Frozen Shoulder Trial
Endo International plc (NASDAQ:ENDP) has announced topline results from its Phase 2 study of collagenase clostridium histolyticum (CCH) in participants with…
Tesla Hit By New Class-Action Lawsuit Claiming Racial Discrimination: Report
Fifteen black employees of Tesla Inc (NASDAQ: TSLA), including former or current, have filed a lawsuit alleging racial abuse and harassment at the company's factories,
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca’s COVID-19 Vaccine
Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc’s (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents…